Lv53
1483 积分 2021-06-03 加入
The promise of menin inhibitors: from approval to triplet regimens
13天前
已完结
Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma
28天前
已完结
Cryoablation plus sintilimab and lenvatinib in advanced or metastatic intrahepatic cholangiocarcinoma: a phase 2 trial
1个月前
已完结
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
1个月前
已关闭
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
1个月前
已完结
Olaparib in treatment‐refractory isocitrate dehydrogenase 1 (IDH1)– and IDH2‐mutant cholangiocarcinoma: Safety and antitumor activity from the phase 2 National Cancer Institute 10129 trial
2个月前
已完结
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
2个月前
已完结
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
3个月前
已完结
A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300-600 mg/day versus benzbromarone 100-200 mg/day in patients with gout
3个月前
已完结
Benzbromarone in the treatment of gout
3个月前
已完结
皖公网安备34019202002308
